Page last updated: 2024-11-05

thalidomide and Enteritis

thalidomide has been researched along with Enteritis in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Enteritis: Inflammation of any segment of the SMALL INTESTINE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, Y1
Han, Z1
Wang, X1
Mo, Z1
Zhang, W1
Li, A1
Liu, S1

Other Studies

1 other study available for thalidomide and Enteritis

ArticleYear
Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.
    BMC gastroenterology, 2013, Dec-09, Volume: 13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Behcet Syndrome; Drug Therapy, Comb

2013